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Alzheimer’s Disease (AD) is the most frequent form of dementia and represents one of the main causes of disability among older
subjects. Up to now, the diagnosis of AD has been made according to clinical criteria. However, the use of such criteria does not
allow an early diagnosis, as pathological alterations may be apparent many years before the clear-cut clinical picture. An early
diagnosis is even more valuable to develop new treatments, potentially interfering with the pathogenetic process. During the
last decade, several neuroimaging and cerebrospinal fluid (CSF) parameters have been introduced to allow an early and accurate
detection of AD patients, and, recently, they have been included among research criteria for AD diagnosis. However, their use in
clinical practice suffers from limitations both in accuracy and availability. The increasing amount of knowledge about peripheral
biomarkers will possibly allow the future identification of reliable and easily available diagnostic tests.
1. Introduction
Autopsy data show that neuropathological features of
AD are associated with subtle cognitive changes among
nondemented subjects, thus suggesting the presence of a
“preclinical Alzheimer’s disease” [1, 2]. Moreover “in vivo”
data based on amyloid PET ligands suggest that accumula-
tion of neuropathologic damage lasts about 20 years before
clear-cut clinical manifestations of the disease [3].
Currently, the diagnosis of AD is made according to
clinical criteria by the National Institute of Neurologi-
cal and Communicative Disorders and Stroke (NINCDS)-
Alzheimer’s Disease and Related Disorders Association
(ADRDA) [4], which have limitations in terms of sensitivity
and specificity and, above all, do not allow an early diagnosis
of the disease.
In the last few years an extensive search for sensitive
and specific biochemical and neuroradiological biomarkers
of AD has been performed. Such markers would also help
to better identify Mild Cognitive Impairment (MCI) patients
at higher risk of conversion to AD. Based on the results of
such studies, research criteria for AD diagnosis have been
proposed which include neuroimaging and cerebrospinal
fluid (CSF) parameters [5].
The main aim of such efforts is to diagnose AD when
neurological damage might still be reversible. This would be
highly valuable in the research setting, as treatments, which
are currently under study to potentially interfere with the
pathogenetic process of the disease, will probably show their
full efficacy only if administered during the prodromal, or
even preclinical, phase of AD. Consistently with this idea,
the first immunization trial against beta-amyloid in full-
blown AD patients showed that, although the treatment was
effective in reducing neuropathological changes, it was not
able to modify the clinical course of the disease [6].
Therefore, while subtle cognitive changes are highly
prevalent among older subjects [7] and neuroradiological
and CSF biomarkers, as discussed below, are not optimal
diagnostic tools in term of availability, accuracy, and inva-
siveness (as in the case of lumbar puncture), the identifica-
tion of reliable and easily accessible peripheral biomarkers
will be of great interest in the setting of AD.
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2. NeuroradiologicalMarkers
Among neuroimaging parameters, the presence of atrophy,
detected with MRI in specific areas of the brain, has been
proposed as an early manifestation of AD [8]. Indeed,
a good correlation seems to exist between hippocampus
atrophy and the extension of neuropathological lesions in
AD brains at autopsy [9]. It has been reported also that
a visual determination of medial temporal lobe atrophy is
a reliable instrument to discriminate AD and MCI from
normal controls and to predict AD conversion in MCI
patients [10]. On the other hand, other studies have reported
that cross-sectional measurements of brain atrophy have
limited diagnostic accuracy among older subjects [11]. This
is consistent with data that show an overlap between AD- and
ageing-associated atrophy in hippocampus and entorhinal
cortex [12].
Among nuclear medicine techniques, the evaluation of
cerebral blood flow by SPECT (Single Photon Emission
Computed Tomography) has a well-established sensitivity in
identifying AD, showing hypoperfusion of temporoparietal
regions and posterior cingulus [13]. Brain metabolism
evaluation by PET (Positron Emission Tomography) with
fluor-deoxyglucose has shown an even greater sensitivity and
a greater spatial resolution, allowing the study of smaller
areas of the brain, such as the hippocampus, of great clinical
interest in AD [14]. Several studies have demonstrated
that PET has a sensitivity of more than 90%, even in the
early phases of the disease, suggesting that it may be able
to differentiate AD from age-related cognitive impairment
[15]. Moreover, PET proved to be a reliable tool for the
identification of MCI patients bound to become AD, with
a diagnostic accuracy which has been proposed to be better
than SPECT and MRI in a recent meta-analysis [16]. On
the other hand, a recent study found no evidence that FDG-
PET is more sensitive than MRI to quantify the degeneration
present in preclinical and mild AD, in specific brain regions
[17]. The authors of this paper suggest that hippocampal
volume, measured by MRI, is probably the best trade-off
between accuracy and convenience for detection of early AD.
In the last few years some “in vivo” PET ligands for AD
lesions have been identified, such as [(11)C]PIB (Pittsburgh
Compound B) that binds specifically beta-amyloid, and
[(18)F]FDDNP (2-(1-{6-[(2-[F-18]fluoroethyl) (methyl)
amino]-2-naphthyl} ethylidene)malononitrile) that binds
both neurofibrillary tangles and beta-amyloid plaques. Their
ability to differentiate AD patients from control subjects
has been demonstrated [18, 19]. Longitudinal studies have
established that the pathological changes identified with
these molecules may occur in preclinical stages of the disease
and may be detected earlier than atrophic changes and
hypometabolism recognized by FDG-PET [20]. On the
other hand, PIB deposition has been shown in about 20%
of normal elderly subjects as well [21] and seems to proceed
at the same rate both in cognitively intact and in cognitively
impaired subjects [22]. These data were confirmed in a
Japanese study, which found no difference in PIB retention
pattern among very mild, mild, and moderate AD. An
AD-like pattern of PIB deposition was also found in 48% of
MCI and 18% of healthy control subjects [23]. Nevertheless,
higher PIB binding has been related to progression to very
mild dementia, independently of age, in 23 out of 159
not cognitively impaired subjects, confirming that PIB
retention must not be considered a benign process [24].
Moreover, both PIB and FDDNP retention have been found
to correlate with different cognitive domains in AD, MCI,
and cognitively normal subjects. In particular an increased
FDDNP binding was specifically associated with episodic
memory impairment, while increased PIB retention was
associated with a broader range of cognitive impairment
[25].
3. CSF Biomarkers
CSF biomolecular markers of AD have been extensively
investigated in recent years. Among them, an increased
concentration of total and hyperphosphorylated tau protein
and a reduction of amyloid β peptide Aβ42 have been
reported in CSF of AD patients [26], with the combination of
the two markers capable of further improving the diagnostic
accuracy to a sensitivity and specificity of nearly 90% [27].
CSF markers accurately predict the risk of AD conversion
in MCI patients, after a 5-year follow-up [28, 29]. Other
authors have shown a strong relation between CSF Aβ42 and
PET with 11C-PIB during prodromal and early phases of AD,
demonstrating that CSF measurements actually parallel the
neuropathological changes that occur inside the brain [30].
Despite their diagnostic accuracy, determination of CSF
Aβ42 and tau levels has several limitations: circadian vari-
ability of their concentration [31], lack of standardization
(use of different techniques or different protocols among
different laboratories) [26], inadequacy of these markers
to accurately discriminate between AD and other types of
dementia, such as vascular and Lewy body dementia [27].
Moreover laboratories able to conduct such determinations
are not widespread, and lumbar puncture is a relatively
invasive procedure. A large-scale multicenter study, aimed
at evaluating CSF Aβ42 and total and hyperphosphorylated
tau-protein as predictors of AD in MCI patients, found
that these CSF biomarkers are able to identify incipient
AD with satisfactory accuracy (sensitivity 83%; specificity
72%; negative predictive value 88%; positive predictive
value 62%), but with inferior power than what is reported
by single-center studies, because of a great intersite assay
variability [32]. The accompanying editorial suggests that the
use of CSF markers, although advised in a research setting,
should not yet be included in clinical practice [33].
Other CSF surrogate markers of brain amyloid deposi-
tion have been proposed. Like Amyloid Precursor-Protein
(APP), Amyloid Precursor like Protein (APLP) undergoes a
metabolic processing by secretases. Higher levels of APLP-1-
derived peptides have been identified in CSF of AD patients,
both in familiar and in sporadic forms [34].
Moreover, lower levels of Sortilin-related receptor
(SORL1, also known as SorLA or LR11) have been identified
in CSF of AD patients compared with cognitively normal
controls and have been proposed as a diagnostic biomarker
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for AD [35]. During the last few years, SORL1 has been
identified as a facilitative factor of intraneuronal APP
redistribution inside the Golgi, increasing its processing in
the nonamyloidogenic pathway, while SORL1 deficit has
been associated to an increased production of Aβ fragment
[36]. In neuropathologic AD samples a reduction of SORL1
protein, compared to controls, was observed [37], that was
inversely related to amyloid plaques and neurofibrillary
tangles [38].
Finally, some studies have focused on products of
oxidative stress to discriminate AD from control subjects (see
also below): higher CSF and plasma isoprostanes level may
represent a marker of oxidative damage in AD [39] and MCI
[40] subjects, compared to controls. Other studies have iden-
tified lower level of antioxidants, in particular superoxide
dismutase (SOD), in CSF of subjects with neurodegenerative
diseases, including AD [41].
4. Peripheral Biomarkers
Lately, several Authors have directed their efforts in iden-
tifying AD biomarkers in plasma or serum, but the results
are still inconclusive. A longitudinal study has found that
high plasma levels of Aβ42 were associated with an increased
risk of developing AD in subjects without dementia. Besides,
conversion to AD was associated with a decrease of plasma
Aβ42 levels and of plasma Aβ42/Aβ40 ratio [42]. This
biphasic trend might be interpreted as follows: higher levels
of Aβ42 are linked to an increased risk, while its subsequent
decline might reflect compartmentalization of the peptide
in the brain. This interpretation is consistent with a recent
study that found an increased risk of dementia after 5 years
in subjects with high plasma levels of Aβ42 [43]. On the
other hand, a previous study found an increased risk of
transition from cognitive normality to MCI or dementia in
subjects with low plasma Aβ42/Aβ40 ratio [44]. Moreover,
a longitudinal study showed that low plasma levels of Aβ42
and Aβ42 in AD patients were significantly associated with a
more rapid functional and cognitive decline [45].
Other putative plasma biomarkers include molecules
involved in the inflammatory response. In particular, higher
level of soluble CD40 (sCD40) is found in plasma of AD
patients compared with age-matched controls [46] and is
able to predict the risk of conversion to AD in a sample
of MCI patients [47]. Moreover, the expression of CD40
cognate ligand, CD40L, is upregulated in AD patients and
is associated with an increased cognitive decline over the
following 2 years [48]. These data are consistent with autopsy
and animal studies that show an enhanced expression of
CD40 and CD40L on astrocytes of AD brains [49].
In agreement with the involvement of inflammation in
the pathogenesis of AD, recently an algorithm based on the
values of several serum proteins, many of whom are related
to inflammation, demonstrated 80% sensitivity and 91%
specificity in discriminating AD from controls; the addition
of gender, age, education, and ApoE status to the prediction
algorithm increased sensitivity and specificity to 94% and
84%, respectively [50]. In a previous study with a similar
approach a different set of plasma signaling proteins was
identified, which was able to correctly differentiate AD from
controls (cognitively normal and other dementia) with 90%
sensitivity and 88% specificity; moreover the same algorithm
showed 91% sensitivity and 72% specificity in predicting
AD development in a small sample of MCI subjects after
2–6 years [51]. Interestingly, the panel of 18 proteins which
allowed dementia prediction in the cited study were involved
in hematopoiesis and inflammation, leading the authors to
hypothesize an impairment in macrophage function in AD
subjects, possibly related to a decreased Aβ clearance from
brain [52].
Other authors have studied the influence of Brain-
Derived Neurotrophic Factor (BDNF), a potential neuro-
protective agent, on neuron survival and function, and
found that its level is significantly higher in serum of AD
and MCI patients, compared with healthy subjects, inde-
pendently of disease severity, treatment with antidepressant
or cholinesterase inhibitors [53]. These data are partially
consistent with another study showing an increase of BDNF
concentration in mild AD, compared with controls (the
result being interpreted as a compensatory mechanism), with
a subsequent decline in later stages of the disease [54]. On the
contrary, another research has found decreased BDNF levels
in MCI subjects, compared with cognitively normal controls
[55].
A different approach is the search for possible AD
biomarkers in peripheral cells, based on the hypothesis that
modifications of signal transduction, oxidative metabolism
or APP metabolism that are present in neurons, may be
found in peripheral tissues as well [56].
Peripheral tissues would constitute an easier model to
study the pathogenesis of AD and to identify biomarkers
of the disease. Until now, several peripheral tissues have
been employed in AD research, including peripheral blood
mononuclear cells (PBMCs), platelets, and fibroblasts. Each
model has advantages and disadvantages, with fibroblasts
being particularly useful, due to high stability under physi-
ological and pharmacological stress [57]. Unlike PBMCs and
platelets, fibroblasts behavior becomes independent from
circulating molecules as soon as the cells are propagated
in vitro. On the other hand, fibroblasts will age in culture,
making it more difficult to interpret the results obtained
with this model. Moreover, PBMCs and platelets are more
accessible and may be a better model when techniques such
as cytofluorimetry are employed.
One possible peripheral cell AD biomarker is represented
by the PKC intracellular signaling system. In cerebral tissues
of AD patients, PKC protein level, activity, and intracellular
translocation are altered compared to control brain tissues
[58]. In fibroblasts of AD patients, a reduced PKC activity
has been described [59]. Moreover, inflammatory stimuli,
such as bradykinin (BK), determine in fibroblasts of AD
patients a PKC-mediated phosphorylation of extracellular
signal-regulated kinases (ERKs) 1/2, which is not detected
in fibroblasts of age-matched healthy controls [60]. A
phospho-ERK1/phospho-ERK2 index, before and after BK
stimulation, has been proposed as AD biomarker, being able
to discriminate not only between AD and healthy subjects,
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but also between AD and non-AD dementia [61]. This index
was validated in a sample which included autopsy-confirmed
cases, demonstrating higher sensitivity and specificity for
diagnosing AD compared with clinical criteria, especially
within the first 4 years from the onset of the disease [62].
Adding to the validity of this result, another study has
observed increased levels of phosphorylated ERK1/2 in CSF
of patients with neurodegenerative conditions (AD, fronto-
temporal dementia, and MCI), suggesting that these kinases
are released into CSF in parallel with tau and phospho-tau
proteins [63].
In a different research line, a conformational modifi-
cation of p53 protein, associated with an alteration of its
transcriptional activity, has been described in skin fibroblasts
isolated from AD patients. This protein misfolding, which
can be induced in non-AD fibroblasts by low concentrations
of Aβ peptide [64], results in an increased resistance of the
cells to p53-mediated apoptosis; therefore, its involvement in
the early phases of amyloid deposition has been hypothesized
and its possible use as a biomarker of early AD proposed
[65]. The same authors have developed a cytofluorimetric
test on PBMC that quantitatively evaluates the amount of
altered p53 present within the cell. Such test has a sensitivity
and a specificity comparable to routine CSF biomarkers
in identifying AD, but only in patients under 70 years
of age. In 70+ subjects, the amount of conformationally
altered p53 increases, independently of the presence of AD;
however, older AD patients still display increased amount of
altered p53 compared to age-matched healthy controls [66].
Moreover the same mutant form of p53 was found to predict
MCI conversion to AD after two years with good specificity
and satisfactory sensitivity [67].
More recently, the same Authors have described an
increase of membrane CD44 expression in lymphocytes of
patients with AD, in comparison with healthy subjects. CD44
is an adhesion molecule involved in the immune response
even inside the central nervous system, and its increase seems
to parallel the rise of unfolded p53 in AD lymphocytes [68].
Another research approach is related to the study of APP
metabolism in platelets, based on data showing functional
similarities between platelets and neurons. In particular, it
has been shown that platelets isolated from AD patients
have a different ratio of APP isoforms, with a lower amount
of high molecular weight APP, compared to cognitively
intact subjects. The “APP ratio” of high and low molecular
weight isoforms is able to accurately discriminate between
AD patients and normal controls [69] and to predict poor
cognitive prognosis in MCI subjects at 2-year follow-up [70].
This test was found to be highly reproducible, with the main
limitation being its sensitivity to pharmacological treatments
(e.g., cholinesterase inhibitors, antiplatelet agents) [71].
Finally, several studies have shown increased markers
of oxidative stress in brain from AD and MCI patients,
compared to controls [72, 73]. Oxidative stress can result
from diminished levels of antioxidants, even if reactive
oxygen species levels are unchanged. A significant decrease
of superoxide dismutase (SOD) has been observed in AD
and MCI patients, compared with controls, both in plasma
[74] and in specific brain areas [75]. In a separate study, the
authors found not only a decrease of SOD and glutathione
levels, but also an increase of lipid peroxidation markers in
serum of AD patients, compared to an age-matched control
group [76]. However, such studies, although adding useful
information on the pathogenetic process of the disease, do
not seem to provide results specific enough to justify their
use as diagnostic tools.
5. Conclusions
During the last several years, our knowledge about possible
biomarkers of AD has increased, paralleling the development
of new therapeutic approaches. CSF and neuroimaging
biomarkers seem to be the most promising; however
limitations regarding their reliability, diffusion, as well as
costs, still remain. In this perspective, the availability of
peripheral biomarkers, less invasive, more readily accessible,
and possibly cheaper, would be of great value. Results in this
field are promising, and some of these biomarkers might
become available in the clinical setting soon.
However, due to the multifactorial nature of AD patho-
genesis, it seems unlikely that a single marker may prove to
be the ultimate diagnostic tool. More likely, a combination
of peripheral biomarkers, along with extensive clinical and
neuropsychological assessment, might be able to suspect
cases of prodromal AD, among the vast number of subjects
with subjective or mild cognitive impairment, to be classified
as “high risk” and to be subjected to more invasive and/or
expensive procedures of functional neuroimaging and CSF
analysis. More research is needed to validate this approach.
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